Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients
Authors:
Open Access
- 1 May 2020
- journal article
- review article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 12 (5) , 2791-2802
Abstract
Chronic obstructive pulmonary disease (COPD) is а highly prevalent, complex and heterogeneous clinical condition which is associated with significant concomitant diseases. COPD and cardiovascular diseases (CVDs) often coexist due to the high prevalence of each of these pathological conditions separately as well as the common risk factors (particularly smoking), mechanisms of interaction and influence of systemic inflammation. In addition, decreased pulmonary function in COPD is closely associated with an increased risk of congestive CVDs. One of the most important pathophysiological markers of COPD—lung hyperinflation—plays a significant role in the appearance of functional limitations of the pumping function of the heart, creating unfavorable conditions by exerting a compression effect on the heart muscle. The latter was confirmed by significant correlation between the COPD severity according to GOLD classification and the basic dimensions of the heart chambers. Several decades ago, the term “microcardia” was commonly used and indicated a radiological sign of emphysema. Some studies demonstrated a close relationship between the chance of occurrence of CVD and the severity of pulmonary dysfunction. Such an association has been demonstrated for the whole spectrum of CVD—including cerebrovascular disease, congestive heart failure (CHF) and rhythm disturbances—and was detected in the early stages of the disease. A large proportion of patients with mild and moderate COPD die due to CVD, which is much more likely than deaths in the same group due to respiratory insufficiency. COPD patients have a higher rate of hospitalization and death, the cause of which are coronary heart disease (CHD), stroke and CHF. Treatment of COPD today is mainly determined by national and international clinical guidelines, which should pay more attention to the problems of the treatment of COPD patients with comorbid conditions.Keywords
This publication has 108 references indexed in Scilit:
- Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohortRespiratory Medicine, 2013
- High-sensitivity cardiac troponin T levels are increased in stable COPDHeart, 2013
- The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008BMC Pulmonary Medicine, 2012
- Comorbidity and Sex-Related Differences in Mortality in Oxygen-Dependent Chronic Obstructive Pulmonary DiseasePLOS ONE, 2012
- Airflow Obstruction, Lung Function, and Risk of Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) StudyEuropean Journal of Heart Failure, 2012
- Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPDEuropean Respiratory Journal, 2012
- New insights into the immunology of chronic obstructive pulmonary diseaseThe Lancet, 2011
- Comorbidities, Patient Knowledge, and Disease Management in a National Sample of Patients with COPDThe American Journal of Medicine, 2009
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPDEuropean Respiratory Journal, 2008